A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

NCT06789913 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA-Related Overgrowth Spectrum (PROS)
Lymphatic Malformations
Vascular Malformations
PIK3CA Mutation
CLOVES Syndrome
Klippel Trenaunay Syndrome
Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

Interventions

DRUG: RLY-2608
DRUG: Placebo

Sponsor

Relay Therapeutics, Inc.